PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise
On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s (“PHI” or the “Company”) rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.
PostNews
BioStock: PHI accelerates growth with record order
PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.
PostNews: Press Release
Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)
The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.
PostNews: Press Release
The last day of trading in warrants of series TO 4 is on 1 October 2024
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
PostNews: Press Release
PHI announces significant order agreement from Altium for 20 HoloMonitor systems
PHI is excited to announce a significant order agreement from Altium for 20 HoloMonitor systems, which will be shipped in the second half of 2024.
PostNews: Interim Report
Interim Report 1 2024/25
The first quarter of 2024 has so far been a period of steady course and strategic positioning for Phase Holographic Imaging. Most notably, PHI has been very active around the globe in forming important academic and sales partnerships during this summer and preparing for future growth.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
BioStock: PHI links up with two regenerative medicine networks
BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
BioStock: PHI charts a bold course to impact regenerative medicine
BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
BioStock: The five best life science stocks of the first half-year
PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
